Minaris Advanced Therapies vs Takeda: CDMO Comparison
How does Minaris Advanced Therapies compare to Takeda for Cell Therapy manufacturing?
Side-by-side comparison of Minaris Advanced Therapies and Takeda on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Takeda has more FDA inspections on record (4 vs 1) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Takeda has materially broader EMA GMP coverage (18 active certificates vs 2) — stronger EU footprint.
- Minaris Advanced Therapies maintains 4 MHRA / UK GMP certificates; Takeda does not.
- Takeda appears as a manufacturing partner on more matched clinical programs (100 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both Minaris Advanced Therapies and Takeda qualify as Cell Therapy manufacturers; Minaris Advanced Therapies carries the higher composite Signal Score for Cell Therapy programs in this comparison.
What to evaluate for Cell Therapy programs
Both Minaris Advanced Therapies and Takeda qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
Frequently asked: Minaris Advanced Therapies vs Takeda
How does Minaris Advanced Therapies compare to Takeda for Cell Therapy manufacturing?
On CDMO Signal's composite Signal Score, Minaris Advanced Therapies is 83/100 and Takeda is 82/100; Minaris Advanced Therapies has 1 FDA inspection on record vs 4 for Takeda; European coverage is 6 active EMA+MHRA certificates for Minaris Advanced Therapies vs 18 for Takeda. Both are tracked in the CDMO Signal directory as Cell Therapy CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Minaris Advanced Therapies or Takeda?
Both Minaris Advanced Therapies and Takeda maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Minaris Advanced Therapies has 1 FDA inspection on record; Takeda has 4.
How do Minaris Advanced Therapies and Takeda compare on European GMP coverage?
Minaris Advanced Therapies holds 2 active EMA GMP certificates and 4 MHRA / UK certificates. Takeda holds 18 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Minaris Advanced Therapies or Takeda?
Minaris Advanced Therapies is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Takeda is matched to 100. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Cell Therapy manufacturing — Minaris Advanced Therapies or Takeda?
Both Minaris Advanced Therapies and Takeda are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →